Sequent Scientific posts 13% revenue growth, 94% profit surge

Sequent Scientific Limited reported revenue of INR4,414 million for Q1 FY '26, up 13.1% year-on-year. Adjusted EBITDA increased 24.7% to INR602 million, with margins expanding to 13.6%. Profit after tax surged 93.7% to INR176 million.

The formulation business grew 13% while the API segment increased 14% to INR1,054 million. The merger with Viyash Group progresses as scheduled, with NCLT meetings set for August 30, 2025.